{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:21:25Z","timestamp":1769005285407,"version":"3.49.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hematopoietic stem cell transplantation (HSCT) offers a potential cure for various hematologic malignancies and non-malignant disorders but is often accompanied by severe complications, one of the most challenging being transplant-associated thrombotic microangiopathy (TA-TMA). Eculizumab, a complement inhibitor, has emerged as an effective therapeutic option for TA-TMA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This single-center retrospective study was conducted at Pavlov University, St. Petersburg, to evaluate the efficacy of eculizumab in 14 adult and pediatric patients who developed high-risk TA-TMA following HSCT between 2015 and 2023. Treatment response was assessed by monitoring organ functions, blood counts, transfusion requirements, the presence of schistocytes in peripheral blood, and increased serum lactate dehydrogenase (LDH). The primary endpoint was overall survival at 100\u202fdays from eculizumab administration. Secondary endpoints included the cumulative incidence of a 25% decrease in serum lactate dehydrogenase levels and to the limit of the normal range for age from the date of the initiation of eculizumab, the cumulative incidence of a 50% increase in platelet count or stable platelet levels \u2265\u202f20\u00d710<jats:sup>9<\/jats:sup>\/l was 74% (95% CI, 32\u201392) with median time 21\u202fdays (range: 1\u2013104), cumulative incidence of platelet level\u202f\u2265\u202f50\u00d710<jats:sup>9<\/jats:sup>\/l, and 1\u202fyear from the date of the initiation of eculizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall survival at 100\u202fdays was 57% (95%CI, 36\u201390). The cumulative incidence of LDH decreased by 25% was 89% (95% CI, 26\u201399) with a median time of 11\u202fdays (range: 2\u201327). Cumulative incidence of LDH\u202f\u2264\u202f1.5 upper reference limits (URLs) after eculizumab therapy was 73% (95% CI, 34\u201391) with a median time of 22\u202fdays (range: 2\u2013170). The cumulative incidence of a 50% increase in platelet level or stable platelet level\u202f\u2265\u202f20\u00d710<jats:sup>9<\/jats:sup>\/l was 74% (95% CI, 32\u201392) with a median time of 21\u202fdays (range: 1\u2013104). The cumulative incidence of platelet level\u202f\u2265\u202f50\u00d7109\/l was 56% (95% CI, 22\u201380) with a median time of platelet increase of 75\u202fdays (range: 5\u2013384). Complete response was documented in 57% of the group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In summary, eculizumab is a well-tolerated promising therapeutic intervention for TA-TMA, but more studies are needed to establish its timing and dosage regimen in TA-TMA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1551066","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T02:13:52Z","timestamp":1743128032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Time course of organ and hematological response to complement blockage in transplant-associated thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"12","author":[{"given":"Tatiana A.","family":"Rudakova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia Yu","family":"Vlasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olesya V.","family":"Paina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga A.","family":"Slesarchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina A.","family":"Gorodnova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana S.","family":"Schegoleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg V.","family":"Goloshchapov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana A.","family":"Bykova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena V.","family":"Morozova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyudmila S.","family":"Zubarovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan S.","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D.","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.intimp.2007.08.006","article-title":"Endothelial cells are a target of both complement and kinin system","volume":"8","author":"Bossi","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1002\/eji.1830211135","article-title":"The role of C5a and antibody in the release of heparan sulfate from endothelial cells","volume":"21","author":"Platt","year":"1991","journal-title":"Eur J Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/bmt.2017.207","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies","volume":"53","author":"Khosla","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic Microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific blood and marrow transplantation group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"266.e1","DOI":"10.1016\/j.jtct.2022.01.009","article-title":"Incidence and risk factors of transplantation-associated thrombotic Microangiopathy: a systematic review and Meta-analysis","volume":"28","author":"Van Benschoten","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/trf.12859","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options","volume":"55","author":"Kim","year":"2015","journal-title":"Transfusion"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1182\/bloodadvances.2021006523","article-title":"Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT","volume":"6","author":"Mizuno","year":"2022","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"564647","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and safety of Eculizumab in the treatment of transplant-associated thrombotic Microangiopathy: a systematic review and Meta-analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6128","DOI":"10.4049\/jimmunol.160.12.6128","article-title":"Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells","volume":"160","author":"Hindmarsh","year":"1998","journal-title":"J Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3390\/medicina58091311","article-title":"Molecular pathogenesis of Endotheliopathy and Endotheliopathic syndromes, leading to inflammation and microthrombosis, and various hemostatic clinical phenotypes based on \u201ctwo-activation theory of the endothelium\u201d and \u201ctwo-path unifying theory\u201d of hemostasis","volume":"58","author":"Chang","year":"2022","journal-title":"Medicina"},{"key":"ref16","first-page":"291","article-title":"The role of the complement system in the pathogenesis of multiple organ failure in shock","volume":"308","author":"Zimmermann","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000236861","article-title":"Role of endothelial cells in transplantation","volume":"106","author":"Robson","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"811504","DOI":"10.3389\/fmed.2022.811504","article-title":"Complement mediated endothelial damage in thrombotic Microangiopathies","volume":"9","author":"Blasco","year":"2022","journal-title":"Front Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2991\/chi.d.190317.001","article-title":"Endothelial dysfunction in hematopoietic cell transplantation","volume":"1","author":"Palomo","year":"2019","journal-title":"Clin Hematol Int"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/s41409-020-0852-2","article-title":"Vascular endothelial syndromes after HCT: 2020 update","volume":"55","author":"Carreras","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref22","first-page":"140","article-title":"Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage","volume":"16","author":"Craddock","year":"1979","journal-title":"Semin Hematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1440-1827.2011.02704.x","article-title":"Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"61","author":"Mii","year":"2011","journal-title":"Pathol Int"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","article-title":"Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"96","author":"Laskin","year":"2013","journal-title":"Transplantation"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"569291","DOI":"10.3389\/fmed.2020.569291","article-title":"Validation of early increase in complement activation marker sC5b-9 as a predictive biomarker for the development of thrombotic Microangiopathy after stem cell transplantation","volume":"7","author":"Mez\u00f6","year":"2020","journal-title":"Front Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","article-title":"Interferon-complement loop in transplant-associated thrombotic microangiopathy","volume":"4","author":"Jodele","year":"2020","journal-title":"Blood Adv"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"601.e1","DOI":"10.1016\/j.jtct.2024.03.019","article-title":"Use of Eculizumab in pediatric patients with high-risk transplantation-associated thrombotic Microangiopathy: outcomes and risk factors associated with response and survival. a retrospective study on behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)","volume":"30","author":"Ben\u00edtez Carabante","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3390\/ijms24021159","article-title":"Transplant-associated thrombotic Microangiopathy in the context of allogenic hematopoietic stem cell transplantation: where we stand","volume":"24","author":"Lazana","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1551066\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T02:14:07Z","timestamp":1743128047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1551066\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":31,"alternative-id":["10.3389\/fmed.2025.1551066"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1551066","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"1551066"}}